Down 35%, Mannkind No Bargain
Feb 23rd 2012 6:39PM
Updated Feb 23rd 2012 6:42PM
The following video is part of our "Motley Fool Conversations" series in which health-care editor/analyst David Williamson and technology editor/analyst Andrew Tonner discuss topics across the investing world.
In today's edition, David discusses the recent capital raise at Mannkind, which hopes to get its inhaled-insulin therapy, Afrezza, on the market. Shares plunged 35% after the news, which seemed to catch the market off guard, but management stated in their Q3 conference call that they would only be able to fund operations through Q1 2012. David argues that even after this overreaction, shares are not a bargain. Even if Afrezza is approved, there may not be as large a market as investors think. Big Pharma has struggled to sell or scrapped inhaled-insulin products, so Mannkind looks to have an uphill climb even if it gets past the FDA.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger."Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published Andrew Tonner has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend MannKind and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.